March 30, 2022 -- Merck announced that it received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending approval for pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors in five different types of cancer.
The anti-programmed death receptor-1 antibody is a monotherapy for the treatment of patients with unresectable or MSI-H/mismatch repair deficient colorectal, gastric, small intestine or biliary cancer, and advanced or recurrent MSI-H/dMMR endometrial carcinoma, the company said.
The CHMP recommendations were based on results from the phase II Keynote-158 and phase II Keynote-164 trials of Keytruda.
The agency’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected in the second quarter of 2022, Merck said in a release.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
